Two National Experts to Review Implications for Plans, PBMs and Pharma of CMS’s New MA and Part D Rule

In a March 6 webinar from Atlantic Information Services, two national experts dissect the specific implications of CMS’s proposed changes for Medicare Advantage and Part D plans, and present strategies for dealing with them on both the business and regulatory sides.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Washignton, DC (PRWEB) February 25, 2014

CMS’s 678-page proposed rule for Medicare Advantage (MA) and Part D plans, released in early January, is breathtaking in its scope. Several years in the making, the draft rule is a clear sign that CMS is strengthening its oversight of MA and Part D plans. “CMS’s Sweeping New Medicare Advantage and Part D Rule: Implications for Plans, PBMs and Pharma,” the March 6 webinar from Atlantic Information Services, will discuss where the pitfalls and opportunities lie among these enormous proposed changes.

Participants will hear from Matthew Eyles, executive vice president of Avalere Health LLC, and Janice Ziegler, a partner in the Life Sciences and Health Care sector team at the law firm Dentons US LLP. In 60 minutes of expert presentations followed by 30 minutes devoted to individual questions, participants will get valuable strategic insights on key questions such as:

  • What would be the impact of the new quality requirements in both MA and Part D contracts?
  • How would the enhanced ability of MA plans to offer rewards and incentives be used? What would be the likely results?
  • How would Part D plans and pharmaceutical manufacturers be impacted by the changes in protected drug classes?
  • How would plans be affected by the significant expansion of the number of beneficiaries eligible for medication therapy management?
  • What are the implications on plans and PBMs of the new standards for preferred cost sharing on drugs? What should plans do in bids for 2015 to prepare for this?
  • How would limiting the number of PDPs to two per sponsor per service area affect PDP market competition and profitability starting in 2016?
  • What would be the likely impact of the proposed requirement that MA plans hire independent compliance auditors to perform audits based on CMS specifications?
  • How would MA markets be affected by the expanded prohibitions on the granting of new MA contracts after the same sponsor terminates a contract in the same service area?
  • What would be the implications of expanded access by researchers to Part D data as proposed by CMS?

Visit http://aishealth.com/marketplace/c4a07_030614 for more details and registration information.

About AIS
Atlantic Information Services, Inc. (AIS) is a publishing and information company that has been serving the health care industry for more than 25 years. It develops highly targeted news, data and strategic information for managers in hospitals, health plans, medical group practices, pharmaceutical companies and other health care organizations. AIS products include print and electronic newsletters, websites, looseleafs, books, strategic reports, databases, webinars and conferences. Learn more at http://www.AISHealth.com.


Contact